Posterior reversible encephalopathy syndrome associated with use of Atezolizumab for the treatment of relapsed triple negative breast cancer. (2022)

• Record Type: Journal Article
• Authors: Foulser, Peter F.G.; Senthivel, Nishanthi; Downey, Kate; Hart, Paul E.; McGrath, Sophie E.
• Is Part Of: Cancer treatment and research communications. Number 31(2022)
• Publication Date: 2022
• Subjects: Posterior reversible encephalopathy -- Atezolizumab -- Breast cancer
• DOI: 10.1016/j.ctarc.2022.100548
• Languages: English
• ISSNs: 2468-2942

Abstract

Abstract: Posterior reversible encephalopathy syndrome (PRES) is a complex neurological disorder with multiple clinical manifestations including headaches, seizures, and altered mental status. It is associated with many conditions including malignancy and medications including chemotherapy and immunotherapy. We report the case of a 56-year old female with a history of advanced triple negative breast cancer treated with atezolizumab (a PD-L1 inhibitor), paclitaxel and ipatasertib (investigational AKT inhibitor), who developed hypertension, confusion, and imaging findings consistent with PRES.